ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
This patent is part of ProQR’s intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules.
- This patent is part of ProQR’s intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules.
- Since then, ProQR has filed multiple additional patent applications on further improvements to form a leading patent estate that supports ProQR’s ADAR-mediated RNA editing platform Axiomer.
- Today ProQR has extensive patent protection related to the Axiomer RNA editing platform, including 15 published patent families, that currently comprise a total of 28 patents.
- Beyond this, ProQR has several unpublished patent applications and continuously invests in expanding its IP estate around ADAR-mediated RNA editing.